Table 2.
Postinfusion outcomes by cytogenetic group
| High risk | Intermediate risk | Favorable risk | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
MLL (KMT2Ar) (n = 25) |
Ph+ (n = 18) |
Ph-like (n = 19) |
Hypodiploid (n = 8) |
TCF3/HLF (n = 4) |
iAMP21 (n = 10) |
IZF1 (n = 10) |
TCF3/PBX1 (n = 8) |
Hyperdiploid (n = 30) |
ETV6/RUNX1 (n = 13) |
Uninformative (n = 86) |
|
| Disease response | |||||||||||
| Complete response | 23 (92%) | 18 (100%) | 16 (84%) | 8 (100%) | 4 (100%) | 10 (100%) | 8 (80%) | 6 (75%) | 29 (97%) | 13 (100%) | 83 (97%) |
| No response | 1 (4.0%) | 0 (0%) | 2 (11%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (10%) | 2 (25%) | 1 (3.3%) | 0 (0%) | 3 (3.5%) |
| Inevaluable* | 1 (4.0%) | 0 (0%) | 1 (5.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Patients with relapse, n (%) | 12 (48%) | 2 (11%) | 3 (16%) | 5 (62%) | 2 (50%) | 2 (20%) | 2 (20%) | 4 (50%) | 6 (20%) | 8 (62%) | 32 (37%) |
| CD19− | 7† | 2 | 2 | 3 | 1 | 0 | 2 | 2 | 3 | 4 | 16‡ |
| CD19+ | 4 | 0 | 0 | 1 | 1 | 2 | 0 | 2 | 2 | 4 | 14 |
| Months of follow-up, median (interquartile range) | 26 (24, 43) | 24 (21, 60) | 30 (15, 45) | 28 (20, 43) | |||||||
*
Three patients died prior to day 28 evaluation from sequelae of cytokine release syndrome, coagulopathy, and infection without clear evidence of progressive disease.
†
Includes 4 patients with lineage switch.
‡
Includes 1 patient with lineage switch.